|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer consists of 3 major tumor subtypes categorized according to estrogen or progesterone receptor expression and ERBB2 gene amplification.
|
30667505 |
2019 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metaplastic carcinomas often contain an admixed conventional ductal invasive or <i>in situ</i> mammary carcinoma component, and are typically triple-negative for estrogen receptor, progesterone receptor, and HER-2 amplification/overexpression.
|
28424200 |
2017 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, upon comparing differentially methylated WA responsive target genes with DNA methylation changes in different clinical subtypes of breast cancer patients in the cancer genome atlas (TCGA), we found that WA silences HER2/PR/ESR-dependent gene expression programs to suppress aggressive TNBC characteristics in favor of luminal BC hallmarks, with an improved therapeutic sensitivity.
|
28467815 |
2017 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 26 successfully retrieved archival NF1 breast tumours were more often associated with unfavourable prognostic factors, such as oestrogen and progesterone receptor negativity and HER2 amplification.
|
27931045 |
2017 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most salivary gland type tumours of the breast are negative for oestrogen and progesterone receptor and lack HER2 gene amplification, therefore they are classified as 'triple negative' tumours.
|
28043647 |
2017 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen and progesterone receptor expression (ESR and PGR, respectively) and an absence of human epithelial growth factor receptor (ERBB2) amplification.
|
29115931 |
2017 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
HMGA1 overexpression was found in the large majority of breast carcinoma samples and its overexpression positively correlated with HER-2/neu amplification and progesterone receptor, while a negative correlation was found with oestrogen receptor.
|
26251519 |
2016 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
-In addition to routine hormone (estrogen and progesterone) receptor testing, new and recurrent tumors are tested for HER2 amplification by in situ hybridization or overexpression by immunohistochemistry.
|
27472240 |
2016 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Triple-negative breast cancers (TNBC), negative for estrogen receptor, progesterone receptor, and ERBB2 amplification, are resistant to standard targeted therapies and exhibit a poor prognosis.
|
25344583 |
2015 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Χ(2) test was used to evaluate the correlation between HER2 gene amplification status and different clinical pathological features including: (estrogen receptor) ER and (progesterone receptor) PR expression, age, menopausal status and tumor size.
|
25674240 |
2014 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear grade, extensive comedonecrosis, stromal architecture, stromal inflammation, and progesterone receptor (PR) expression were significantly associated with HER2 amplification status.
|
24973889 |
2014 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with VEGFA amplification and triple-negative breast cancers (TNBC) or HER2 amplification had inferior OS (P = 0.047); amplification did not affect OS for those who were ER+ or PR+ and HER2-.
|
23340303 |
2013 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
African American (AA) women have a higher incidence of triple-negative breast cancer (TNBC: negative for the expression of estrogen receptor, progesterone receptor, and HER2 gene amplification) than Caucasian (CA) women, explaining in part their higher breast cancer mortality.
|
23400579 |
2013 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers.
|
22495314 |
2012 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Basal-like breast cancers (BLBC) compose up to 15% of BC and are characterized by lack of estrogen receptor (ER), progesterone receptor (PR), and HER-2 amplification with expression of basal cytokeratins 5/6, 14, 17, epidermal growth factor receptor (EGFR), and/or c-KIT.
|
22234518 |
2012 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deletion of ESR1 was associated with significantly lower levels of ER (P < 0.0001) and PgR (P = 0.02) and more frequent HER2 amplification.
|
21986093 |
2012 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-myc and HER2 amplification were examined by FISH, and oestrogen receptor (ER), progesterone receptor (PR), Ki67, and topoisomerase 2α (TOP2A) expression were examined immunohistochemically.
|
21741827 |
2011 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, ER but not PR expression is inversely correlated with Her2 gene amplification.
|
21623202 |
2011 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with CLCIS, PLCIS showed significantly higher Ki67 index, lower estrogen receptor and progesterone receptor expression, and higher incidence of HER2 gene amplification.
|
19701073 |
2009 |
|
HER2 gene amplification
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One well-defined subtype of breast cancer is characterized by a lack of HER2 gene amplification and estrogen and progesterone receptor expression ('triple-negative tumors').
|
17910759 |
2007 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prognostic and therapeutic implications of HER-2 gene amplification and estrogen and progesterone receptor status in breast cancer are well described.
|
16753605 |
2006 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of these frequencies using chi-square test revealed statistically significant correlation between Her-2/neu amplification and ductal versus lobular carcinoma (p<0.0003), ER (p=0.0001) and PR (p<0.0001) negative tumors, over-expression of MIB-1 (p<0.0005) and high tumor grade (p=0.0009), while size of the tumor (p=0.08) and age of the patients (p=0.67) were not statistically significant.
|
15982396 |
2005 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor (ER), progesterone receptor, erbB2, p53, and Ki-67 expression was determined from tumor tissue microarrays using immunohistochemistry, and the erbB2 (HER-2) amplification status was determined using chromogenic in situ hybridization.
|
12631589 |
2003 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a subset study, the negativity of the progesterone receptor content was correlated with HER-2/neu amplification in the node positive (p = 0.02), the pre-menopausal (p = 0.04) and the pre-menopausal node positive (p = 0.002) patients.
|
8097388 |
1993 |
|
HER2 gene amplification
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2/neu amplification was negatively correlated with oestrogen receptor (ER) and progesterone receptor (PR) status (P less than 0.0001; for both), c-myc amplification was more prevalent in the PR-negative subpopulation (P less than 0.05) and int-2/bcl-1 amplification was positively correlated with ER status (P less than 0.001).
|
1350457 |
1992 |